Evolution of high-dose cisplatin

Walter M. Holleran, Michael W. DeGregorio

Research output: Contribution to journalArticle

21 Scopus citations

Abstract

High-dose cisplatin therapy, defined as 200 mg/m2/course, is currently undergoing extensive clinical trials in a variety of solid tumors. The reduction of the incidence and severity of cisplatin-induced nephrotoxicity has led to clinical trials of higher doses of cisplatin. By maintaining nephrotoxicity to acceptable levels, dose response relationships have shown increased efficacy of cisplatin therapy. However, new dose-limiting toxicities, primarily severe neurotoxicity and myelosuppression, have prevented further dosing increases. The following review will trace the evolution and the current status of high-dose cisplatin therapy. In addition, a summary of the dose-limiting non-renal toxicities and their relationship to pharmacokinetics and dosing schedules will be discussed.

Original languageEnglish (US)
Pages (from-to)135-142
Number of pages8
JournalInvestigational New Drugs
Volume6
Issue number2
DOIs
StatePublished - Jun 1988

Keywords

  • cisplatin
  • high-dose
  • toxicities

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Fingerprint Dive into the research topics of 'Evolution of high-dose cisplatin'. Together they form a unique fingerprint.

  • Cite this

    Holleran, W. M., & DeGregorio, M. W. (1988). Evolution of high-dose cisplatin. Investigational New Drugs, 6(2), 135-142. https://doi.org/10.1007/BF00195372